Table 2.

Univariate Cox proportional hazard regression analysis for prediction of cancer-specific survival in T1HG patients > 80 years

Clinicopathological features		HR	95% CI	p
Age		1.046	0.92–1.19	NS
BCG induction	(Yes vs no)	0.271	0.08–0.96	0.044
Number of BCG courses		0.514	0.26–1.04	0.062
Male gender	(Yes vs no)	0.350	0.12–1.03	0.057
Grade (yes vs no)	(3 vs 2)	4.389	0.56–34.08	0.16
Concomitant CIS	(Yes vs no)	0.602	0.08–4.73	NS
Recurrent tumour	(Yes vs no)	0.994	0.35–2.85	NS
Multiple tumours	(Yes vs no)	1.724	0.59–5.08	NS
Tumour size ≥ 3 cm	(Yes vs no)	2.240	0.79–6.34	0.13
Muscle in TURBT specimen	(No vs yes)	2.998	0.95–9.48	0.062
No. of tumours	(> 3 vs ≤ 3)	2.409	0.81–7.14	0.11
HG tumour history	(Yes vs no)	1.381	0.47–4.07	NS
reTURBT	(Yes vs no)	0.635	0.22–1.87	NS
Tumour in reTURBT	(Yes vs no)	1.757	0.48–6.48	NS
HG tumour in reTURBT	(Yes vs no)	2.031	0.57–7.23	NS
Comorbidities
Hypertension	(Yes vs no)	5.445	0.70–42.11	0.10
Coronary artery disease	(Yes vs no)	0.661	0.24–1.84	NS
Myocardial infarction	(Yes vs no)	1.188	0.33–4.25	NS
COPD	(Yes vs no)	1.765	0.60–5.18	NS
Diabetes mellitus type 2	(Yes vs no)	0.833	0.27–2.62	NS
History of other cancer	(Yes vs no)	1.020	0.29–3.63	NS
Atrial fibrillation	(Yes vs no)	0.631	0.18–2.24	NS
Heart failure	(Yes vs no)	1.765	0.60–5.12	NS
UTUC	(Yes vs no)	5.445	0.70–42.11	0.10
Other
Charlson comorbidity index		1.514	0.98–2.35	0.064
ASA		1.104	0.56–2.18	NS
Haemoglobin		0.976	0.95–1.00	0.089
NLR		1.080	0.88–1.33	NS
CUETO recurrence score		1.119	0.95–1.31	0.17
CUETO progression score		1.186	0.86–1.63	NS
EORTC recurrence score		1.207	1.00–1.46	0.051
EORTC progression score		1.095	0.96–1.25	NS

HR hazard ratio, CI confidence interval, CIS carcinoma in situ, reTURBT restaging transurethral resection of bladder tumour, COPD chronic obstructive pulmonary disease, UTUC upper tract urothelial cancer, ASA American Society of Anaesthesiologists Score, NLR neutrophil-to-lymphocyte ratio, The bold values indicate p < 0.1 values